iShares Core High Dividend ETF vs Tempus AI — how do they compare? iShares Core High Dividend ETF trades at $28.77 (market cap $14.68B), while Tempus AI trades at $70.03 (market cap $12.58B). The key difference: iShares Core High Dividend ETF is the larger of the two by market cap, and iShares Core High Dividend ETF is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Tempus AI for 22 Days on average.
| HDV | TEM | |
|---|---|---|
Market Cap | $14.68B | $12.58B |
Volume | 2,925,562 | 7,444,569 |
52-Week High | $29.93 | $99.28 |
52-Week Low | $23.64 | $41.55 |
Typical Hold Time | 117 Days | 22 Days |
Sector | — | Broad Market / Factor |
Enterprise Value | — | $13.21B |
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.28, down 0.28% on the day, with technical indicators showing a neutral to bearish bias. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure by nearly half while increasing energy, staples, and utilities. This shift creates heightened concentration risk with 62% of assets in just three sectors, offering a 3% yield that may not adequately compensate for reduced diversification according to Seeking Alpha analysis from September 28, 2026.
The outlook remains cautious as HDV's sector concentration and modest yield face headwinds from rising interest rates. While high-dividend ETFs are outperforming the S&P 500 in 2026 according to 24/7 Wall Street, HDV's structural changes introduce execution risk. Investors should weigh the trade-off between current income and long-term diversification benefits, particularly as the Fed continues tightening monetary policy.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →